Assessment of PENG Block as a Part of Multimodal Analgesia Following Hip Surgeries.

NCT ID: NCT06916000

Last Updated: 2025-04-08

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-27
• Study Completion Date: 2025-06-30

Brief Summary

to study the effect of Pericapsular nerve group (PENG) block as a part of multimodal analgesia regimen for hip arthroplasties

Detailed Description

PENG block is a novel block described by Giron-Arango in 2018 to anesthesize the anterior hip capsule as it is supplied by branches from femoral, obturator and accessory obturator nerves, sparing motor function is an additional significance So currently the block is used to reduce post operative opioid consumption, delay time rescue analgesia, facilitate positioning for spinal anesthesia for hip surgeries and to accelerate mobility and so hospital discharge saving this vulnerable group of patient from any hospital acquired pneumonia, decreasing hospital stays, and improving recovery times would provide valuable insights into its cost-effectiveness and long-term benefits for healthcare system Our primary outcome to be studied is pain assessment via Numer Rating Scale over 24 hours postoperatively, in addition to to secondary outcomes including the aforementioned advantages.

Conditions

Anesthesia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

PENG block group (25 particiants)

For postoperative pain management, all patients of this arm will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango.

In addition, multimodal analgesia will be given including IV paracetamol 1000 mg BID and oral celecoxib tablet 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as demand dose and when the NRS pain score was equal to or greater than 4 points.

Group Type: ACTIVE_COMPARATOR

Pericapsular nerve group (PENG) block

Intervention Type: DRUG

As a part of multimodal analgesia patients will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango.

All patients will receive the same analgesic protocol, which included IV paracetamol 1000 mg BID and NSAIDs if no contra-indication; PO celecoxib 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as bolus demand dose and when the NRS pain score was equal to or greater than 4 points.

Group C: control group (25 participants)

Patients will receive only other multimodal analgesics

Group Type: EXPERIMENTAL

Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.

Intervention Type: OTHER

Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.

Interventions

Pericapsular nerve group (PENG) block

As a part of multimodal analgesia patients will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango.

All patients will receive the same analgesic protocol, which included IV paracetamol 1000 mg BID and NSAIDs if no contra-indication; PO celecoxib 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as bolus demand dose and when the NRS pain score was equal to or greater than 4 points.

Intervention Type: DRUG

Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.

Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age group: 18 years and older.
• ASA classification I to III.
• BMI : 18-35 .
• Gender: both sex

Exclusion Criteria

• Patient refusal.
• Patients on long-term pain medications.
• History of allergic reactions to local anesthetics
• Patients who had mental illness or uncooperative patients.
• BMI > 35 .
• Patients having coagulopathies or on anticoagulant or antiplatelet therapy.
• Severe cardiopulmonary disease
• ASA IV or more
• Diabetic or other neuropathies

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ain Shams University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Faculty of medicine, Ain Shams University

Abbasia, Cairo Governorate, Egypt

Countries

Egypt

Other Identifiers

FMASU MS428/2024

Identifier Type: -

Identifier Source: org_study_id